Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What's the motivation, is it masochism or sadism??
It's certainly NOT providing information!
Congrats to Whata for digging up that little chestnut!
So let's see, from the article:
Management seems to have improved substantially overnight!!!
Keeping on eye on further developments today.
Will reassess later. Stay tuned!
I call it "Management Plasticity", a syndrome that manifests itself in rapid fluctuations in quality and execution (VERY PRECIPITOUS changes in PPS ..., radical shifts in hours!)
Perhaps a new indication for Lupkynis (assuming kidney involvement)
Dear Melon4head,
I think the decision you made with respect to PSTI is valid, given YOUR analysis of the company's chances, and taking into account a whole range of personal factors, including financial goals, personal status, and a whole range of other factors.
As for me, even-though I'm disappointed with the pace of progress (on the PPS side, not the science and technology), I'm still a believer in the technology and the ability of Pluristem to find the right niche (or niches) to bring the accumulated knowledge to fruition in the market place.
Stem cell technology is moving forward, and it's important to be aware that no company has had a huge marked breakout as yet. But I do believe it's coming, and also that Pluristem has a good chance of participating. If they do, it will be big! This is MY analysis, and it's as good or bad as yours.
In any case, I regret that you are leaving, we need as many civilized, reasonable commentators on this board as we can get.
Best of Luck in your future endeavors!
- sales of $23.21 million for the current quarter
- posted sales of $50.03 million in the same quarter last year,
- will report full year sales of $45.39 million for the current financial year
That makes no sense!
The only thing "obvious" is Death and Taxes (slight paraphrase).
You have no clue how much time till the big BO, nor whether some buyer and management converge on price.
Big pharma might just decide that it's better to pay a bit more now (then much more later) and in the meanwhile they can fully control the clinical and business implementation. Nothing "obvious" here (except cervelo's consistent low expectations).
Fraud!! teaser!! LOL!
Lets see, the rumor is that Novartis is interested in a bolt-on.
Going from "bolt-on" to Pluristem is a bit of a stretch. Even the spelling is different!